Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started ...

Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran ...

Fintel reports that on June 11, 2025, Raymond James initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Strong ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.42, along with a high estimate of $75.00 and a low estimate of $54.00. Surpassing the ...

SOURCE Avidity Biosciences, Inc. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered ...

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.

On Monday, BofA Securities analyst Tazeen Ahmad raised the price target on Avidity Biosciences (NASDAQ: RNA) shares to $54.00, up from the previous $48.00, while maintaining a Buy rating on the stock.